Question explored with the scientific record
Was the Covid mRNA vaccine a better treatment than Ivermectin
The mRNA vaccine reduced all-cause death in large population studies; ivermectin showed no significant effect on mortality in the largest meta-analysis of randomized trials.
The question asks which was a better treatment for people who already had COVID-19. The largest meta-analysis of 40 randomized controlled trials (23,243 participants) found ivermectin had no statistically significant effect on all-cause mortality in either hospitalized patients (RR 0.94, 95% CI 0.74 to 1.20) or outpatients (RR 0.88, 95% CI 0.55 to 1.42) [3]. It also did not shorten time to symptom resolution in a separate randomized trial [4]. The evidence for ivermectin as a treatment is null.
The mRNA vaccine was never studied as a treatment for active COVID-19. The large population studies in the evidence measured its effect as a preventive intervention given before infection. The Norwegian cohort of 4.6 million adults found that people who received three or more mRNA doses had about a 60% lower all-cause mortality rate than unvaccinated people during 2021-2023 [1]. A Danish study of 101,786 heart failure patients found a small but statistically significant lower 90-day mortality in vaccinated patients compared to a matched pre-pandemic cohort [2].
The comparison is apples to oranges. For treating active COVID-19, ivermectin has been tested in many randomized trials and failed to show a benefit. The mRNA vaccine was never tested as a treatment. For preventing severe outcomes before infection, the vaccine has large population studies showing lower mortality.
| Intervention | Question tested | Best evidence | Result |
|---|---|---|---|
| Ivermectin as treatment | Mortality in COVID-19 patients | Meta-analysis of 40 RCTs (23,243 people) [3] | No significant effect (RR 0.94 hospitalized, 0.88 outpatient) |
| mRNA vaccine as treatment | Mortality in COVID-19 patients | No randomized trials exist | Not studied |
| mRNA vaccine as prevention | All-cause mortality in general population | Norwegian cohort (4.6 million) [1] | ~60% lower mortality with 3+ doses |
My call: for treating active COVID-19, ivermectin has been tested and shown no benefit; the mRNA vaccine was never tested as a treatment. Confidence: high.
Sources used 4
-
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study
In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…
DOI: 10.1093/eurheartj/ehac544.881 -
The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials
In 40 RCTs (23,243 participants), ivermectin showed no statistically significant preventive or therapeutic benefit for SARS-CoV-2 infection, with no significant effects on infection rate, mortality, adverse events, or most secondary outcomes.
DOI: 10.1186/s12879-026-13195-9 -
Covid-19: Effects of Azithromycin/Hydroxychloroquine/Ivermectin in ambulatory and hospitalized patients
This systematic review of 17 studies found limited, low-quality evidence that azithromycin, hydroxychloroquine, and ivermectin provide no clinical benefit in COVID-19 outpatients or inpatients.
DOI: 10.54034/mic.e1231